Effect of Ramosetron on Bowel Motility After Gynecological Surgery
- Registration Number
- NCT02849483
- Lead Sponsor
- Kyunghee University Medical Center
- Brief Summary
Ramosetron is effective in preventing postoperative nausea and vomiting. Several studies reported that ramosetron is also effective treatment of irritable bowel syndrome. The investigators examine the effect of ramosetron on postoperative bowel motility.
- Detailed Description
Ramosetron, a new potent and long-acting selective 5-HT3(5-hydroxytryptamine3) receptor anatagonist, is effective for preventing postoperative nausea and vomiting. Also several studies reported that ramosetron is effective treatment of diarrhea-predominant irritable bowel syndrome because it inhibits the accelerated colonic transit, abnormal colonic water transport, defecation abnormality, and the lowered colonic perceptual threshold by corticotrophin-releasing hormone, There is no study about the effect of ramosetron used for preventing postoperative nausea and vomiting on postoperative bowel motility. In this study, the investigators examine the effect of ramosetron on postoperative bowel motility.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 88
- 20-70 yrs of age
- ASA(American Society of Anesthesiologists) physical status class I or II
- Scheduled for gynecological laparoscopic surgery
- Allergic to study drugs
- Antiemetics or steroids use within 24 hrs prior to surgery
- Dependence upon opioids
- Insulin dependent Diabetes Mellitus
- Cardiovascular or pulmonary disease
- Renal or hepatic insufficiency
- BMI>=35kg/m2
- History of motion sickness or PONV
- Cigarette smoker
- Conversion to open laparotomy from laparoscopic surgery
- Pregnants
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control Normal saline dexamethasone 10 mg iv before induction, 2 ml of normal saline iv at the end of surgery, 4 ml of normal saline added to the iv PCA Ramosetron Ramosetron 2 ml of normal saline iv before induction, ramosetron 0.3 mg iv at the end of surgery, ramosetron 0.6 mg added to the iv PCA(Patient-Controlled Analgesia)
- Primary Outcome Measures
Name Time Method Time from surgery to the passage of first flatus Within 10 days after surgery
- Secondary Outcome Measures
Name Time Method Incidence of postoperative ileus Within 10 days after surgery Time to first defecation Within 10 days after surgery
Trial Locations
- Locations (1)
Kyung Hee University Hospital
🇰🇷Seoul, Korea, Republic of